Patents by Inventor Chunlin Tao

Chunlin Tao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240254523
    Abstract: Provided are a genetically engineered strain for producing polylactic acid and a method for producing polylactic acid. The genome of the genetically engineered strain is integrated with a coding sequence of exogenous D-lactate dehydrogenase gene, a coding sequence of exogenous propionyl-CoA transferase gene, and a coding sequence of exogenous polyhydroxyalkanoate synthase gene, enabling the genetically engineered strain to express exogenous D-lactate dehydrogenase, exogenous propionyl-CoA transferase, and exogenous polyhydroxyalkanoate synthase. The method includes: providing the above genetically engineered strain of Synechococcus elongatus; introducing carbon dioxide and culturing the genetically engineered strain under light; and when a growth OD of the genetically engineered strain reaches the maximum, collecting and drying the genetically engineered strain, and recycling the polylactic acid in the strain.
    Type: Application
    Filed: March 18, 2024
    Publication date: August 1, 2024
    Inventors: Fei TAO, Chunlin TAN, Ping XU
  • Publication number: 20240132493
    Abstract: Described herein, inter alia, are imidazopyridine derivatives (I), pharmaceutically acceptable salts and tautomers thereof, compounds, combinations and medicaments containing said compounds and processes for their preparation. In embodiments, the imidazopyridine derivatives can be used as regulators of a stimulator of interferon genes (STING) and a related signal path thereof, and can effectively treat and/or relieve multiple types of diseases, including but not limited to malignant tumors, inflammations, autoimmune diseases, infectious diseases and as vaccine adjuvants.
    Type: Application
    Filed: November 22, 2023
    Publication date: April 25, 2024
    Inventors: Ming HSIEH, Jingcun ZANG, Chunlin TAO
  • Patent number: 11011273
    Abstract: The present inventive subject matter provides apparatus, systems, and methods in which a diagnostic test is identified, where the diagnostic test is for determining whether a particular treatment is effective for a particular patient based on one or more characteristics of a patient's cells. When a treatment is developed with the potential to treat one or more diseases, the drug can have different effects on different cell lines related to the diseases. A machine learning system is programmed to infer a measurable cell characteristic, out of many different measurable cell characteristics, that has a desirable correlation with the sensitivity data of different cell lines to a treatment. The machine learning system is programmed to then determine, based on the correlation, a threshold level of the cell characteristic the patient should exhibit in order to recommend administering the treatment.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: May 18, 2021
    Assignee: NantOmics, LLC
    Inventors: Stephen Charles Benz, Shahrooz Rabizadeh, Christopher Szeto, Paul Weingarten, Chunlin Tao
  • Patent number: 10800760
    Abstract: The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: October 13, 2020
    Assignee: NANTBIO, INC.
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Patent number: 10766879
    Abstract: The present invention provides antitumor agents comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof, methods for making novel compounds and methods for using the compounds. The compounds and compositions in accordance with the invention have utility in treatment of a variety of diseases and have kinase inhibitory activities.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: September 8, 2020
    Assignee: NANTBIOSCIENCE, INC.
    Inventors: Chunlin Tao, Qinwei Wang, Laxman Nallan, David Ho, Tulay Polat, Forrest Arp, Paul Weingarten
  • Patent number: 10738033
    Abstract: The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. The present invention also provides compounds of the formula: as defined herein.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: August 11, 2020
    Assignee: NANTBIO, INC.
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Publication number: 20200165225
    Abstract: Compounds, pharmaceutical compositions containing the same useful in the treatment of Alzheimer's disease are disclosed. Methods of preparing the compounds and compositions and use thereof are also disclosed.
    Type: Application
    Filed: May 8, 2018
    Publication date: May 28, 2020
    Applicant: NantBio, Inc.
    Inventors: Chunlin TAO, Tulay POLAT, Chengzhi YU
  • Patent number: 10487078
    Abstract: Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: November 26, 2019
    Assignees: NantBio, Inc., NantOmics, LLC, Nant Holdings IP, LLC
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Oleksandr V. Buzko, Paul Weingarten, Heather McFarlane, Anna Juncker-Jensen, Justin Golovato, Patrick Soon-Shiong, Chunlin Tao, David Ho
  • Patent number: 10392397
    Abstract: Pharmaceutical compounds, compositions, and methods are presented in which various heterocyclic thiosemicarbazone derivatives are prepared. Contemplated compounds will be suitable to inhibit or reduce cellular growth or proliferation and are thus beneficial in the manufacture of drugs to treat neoplastic diseases.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: August 27, 2019
    Assignees: NantBio, Inc., Nant Holdings IP, LLC
    Inventors: Chunlin Tao, Qinwei Wang, Patrick Soon-Shiong
  • Patent number: 10344026
    Abstract: Compounds and compositions are presented that inhibit K-Ras, and especially mutant K-Ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: July 9, 2019
    Assignee: NantBio, Inc.
    Inventors: Chunlin Tao, Laxman Nallan, David G. Ho, Qinwei Wang, Paul Weingarten, Anna B. Juncker-Jensen
  • Patent number: 10245261
    Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: April 2, 2019
    Assignee: NantBio, Inc.
    Inventors: Chunlin Tao, Qinwei Wang, David Ho, Tulay Polat, Laxman Nallan, Patrick Soon-Shiong
  • Patent number: 10183013
    Abstract: The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 22, 2019
    Assignee: Nant Holdings IP, LLC
    Inventors: Chunlin Tao, Chengzhi Yu, Forrest Arp, Paul Weingarten, Patrick Soon-Shiong
  • Patent number: 10160749
    Abstract: The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: December 25, 2018
    Assignee: NantBio, Inc.
    Inventors: Chunlin Tao, Qinwei Wang, David Ho, Tulay Polat, Laxman Nallan, Patrick Soon-Shiong
  • Publication number: 20180346451
    Abstract: The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Publication number: 20180346450
    Abstract: The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Chunlin Tao, Qinwei Wang, Sharif Asad, Paul Weingarten, Sherry Ci
  • Publication number: 20180318473
    Abstract: The invention provides a medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The invention also provides a method of treating a narrowing in a body passageway comprising placing an implantable medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The medicaments can be incorporated within or coated on the device. The invention further provides hydrophobic analogs of medicaments known to inhibit cell proliferation and migration.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 8, 2018
    Inventors: Neil P. Desai, Chunlin Tao, Cheng Zhi Yu, Qinwei Wang, Patrick Soon-Shiong
  • Publication number: 20180289620
    Abstract: The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.
    Type: Application
    Filed: January 24, 2018
    Publication date: October 11, 2018
    Inventors: NEIL P. DESAI, Chunlin TAO, Tapas DE, Sherry Xiaopei CI, Vuong TRIEU
  • Publication number: 20180215734
    Abstract: The present invention provides kinase inhibitors with anti-proliferative activity comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof. In addition, the invention provides methods for making novel compounds and methods for using the compounds.
    Type: Application
    Filed: February 29, 2016
    Publication date: August 2, 2018
    Inventors: Chunlin Tao, Qinwei Wang, Laxman Nallan, David Ho, Tulay Polat, Forrest Arp, Paul Weingarten
  • Publication number: 20180208603
    Abstract: Pharmaceutical compounds, compositions, and methods are presented in which various heterocyclic thiosemicarbazone derivatives are prepared. Contemplated compounds will be suitable to inhibit or reduce cellular growth or proliferation and are thus beneficial in the manufacture of drugs to treat neoplastic diseases.
    Type: Application
    Filed: August 8, 2016
    Publication date: July 26, 2018
    Inventors: Chunlin TAO, Qinwei WANG, Patrick SOON-SHIONG
  • Publication number: 20180201610
    Abstract: Compounds and compositions are presented that inhibit K-Ras, and especially mutant K-Ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
    Type: Application
    Filed: January 18, 2018
    Publication date: July 19, 2018
    Inventors: Chunlin Tao, Laxman Nallan, David G. Ho, Qinwei Wang, Paul Weingarten, Anna B. Juncker-Jensen